

Sell	(Hold)
EUR 57.00	(EUR 54.00)
Price Downside	EUR 69.49 -18.0 %

Value Indicators:	EUR	Share data:		Description:	
DCF:	57.38	Bloomberg:	AOF GR	ATOSS supplies software and	
		Reuters:	AOFG	services for the optimisation of	f
		ISIN:	DE0005104400	workforce management.	
Market Snapshot:	EUR m	Shareholders:		Risk Profile (WRe):	2016e
Market cap:	276.3	Freefloat	32.7 %	Beta:	1.2
No. of shares (m):	4.0	Founding Famely	56.4 %	Price / Book:	17.0 x
EV:	259.9	Mainfirst	5.1 %	Equity Ratio:	51 %
Freefloat MC:	90.4	Investment TGV Bonn	5.8 %		
Ø Trad. Vol. (30d):	144.45 th				

Still excellently positioned; Considerable rise in the share price

ATOSS Software - Q1	2015						
Angaben in Mio. EUR	Q1/15	Q1/15e	Q1/14	yoy	2015e	2014	yoy
Umsatz	10,7	11,0	9,7	10,4%	44,9	45,2	-0,6%
EBIT Marge	2,8 25,9%	2,9 26,4%	2,5 26,0%	9,7%	11,3 25,2%	11,5 25,4%	-1,2%
EPS in EUR	0,57	0,60	0,50	14,0%	1,91	1,94	-1,5%


Comment on Figures:

- · Atoss Software AG announced preliminary figures for the first quarter of 2016 on 22.04.16.
- Operatively, the figures were in line with expectations.

With the announcement of preliminary Q1 figures, ATOSS Software AG once again provides evidence of the impressive consistency with which the company has shown steadily rising revenue and earnings over the past eleven years standing. ATOSS is met with constant demand in the market for workforce management solutions. At the same time, the unchanged and consistent PoC-based consideration of licence revenues in the earnings assessment provides for a high level of regularity in the development of earnings. Against this background, the forecasts for 2016 remain unchanged.

The ATOSS share price level, however, now lies well above the derived fair value. The reason for the high share price level could be connected to the anticipated dividend of EUR 2.80 expected with the annual figures. This special dividend of 150% of the result (EPS 2015) is well in excess of ATOSS's typical payout ratio of ca. 50% of the net result. In 2013, there was a similar share price development in the context of a special dividend. For no fundamental reason, the over-valuation of the share gradually declined following the payment of the dividend.

Against this background, the rating of the ATOSS share is changed from Hold to Sell with a slightly higher price target of EUR 57 (previously: EUR 54; adjustment based on roll-over effect). This downgrade is not connected to the figures, which were good, or the unchanged excellent strategic position of the company, but is solely valuation-induced.



Rel. Performance vs CDAX:	
1 month:	5.8 %
6 months:	40.7 %
Year to date:	5.6 %
Trailing 12 months:	64.1 %
Company events:	

FY End: 31.12.	CAGR							
in EUR m	(15-18e)	2012	2013	2014	2015	2016e	2017e	2018e
Sales	12.0 %	33.0	35.5	39.7	44.9	50.3	56.4	63.1
Change Sales yoy		4.5 %	7.6 %	11.8 %	13.2 %	12.0 %	12.0 %	12.0 %
Gross profit margin		70.8 %	71.0 %	68.8 %	68.5 %	71.0 %	71.0 %	71.0 %
EBITDA	12.3 %	8.2	9.0	10.3	12.0	13.6	15.2	17.0
Margin		24.8 %	25.4 %	26.0 %	26.8 %	27.0 %	27.0 %	27.0 %
EBIT	12.4 %	7.6	8.4	9.8	11.3	12.8	14.4	16.1
Margin		23.1 %	23.7 %	24.7 %	25.2 %	25.5 %	25.5 %	25.5 %
Net income	12.5 %	5.8	2.9	7.0	7.6	8.6	9.6	10.8
EPS	12.4 %	1.45	0.72	1.77	1.91	2.16	2.42	2.71
EPS adj.	12.4 %	1.45	0.72	1.77	1.91	2.16	2.42	2.71
DPS	-21.4 %	3.62	0.72	0.88	2.80	1.08	1.21	1.36
Dividend Yield		17.9 %	2.7 %	3.0 %	6.0 %	1.6 %	1.7 %	1.9 %
FCFPS		0.75	1.02	1.94	1.84	2.02	2.31	2.60
FCF / Market cap		3.7 %	3.8 %	6.6 %	4.0 %	2.9 %	3.3 %	3.7 %
EV / Sales		1.7 x	2.7 x	2.6 x	3.7 x	5.2 x	4.5 x	4.0 >
EV / EBITDA		7.0 x	10.5 x	9.9 x	13.7 x	19.1 x	16.8 x	14.9 >
EV / EBIT		7.5 x	11.3 x	10.4 x	14.5 x	20.2 x	17.7 x	15.8 >
P/E		14.0 x	37.3 x	16.8 x	24.3 x	32.2 x	28.7 x	26.1)
P / E adj.		14.0 x	37.3 x	16.8 x	24.3 x	32.2 x	28.7 x	26.1 >
FCF Yield Potential		8.7 %	7.7 %	6.5 %	4.8 %	3.4 %	3.9 %	4.4 %
Net Debt		-23.2	-11.9	-15.9	-19.6	-16.5	-21.4	-26.9
ROCE (NOPAT) Guidance:	Continued pos	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a


12.08.16

25.10.16

Ω2

Q3






Company Background

- ATOSS Software AG is a supplier of software and services for the optimisation of workforce management.
- ATOSS solutions optimises companies' personnel procedures, improving the level of service and efficiency of the employees and improving customer satisfaction
- The company has achieved a leading market position, particularly in the German speaking countries.
- From medium-sized companies (Mittelstand) to blue-chip firms, several million employees use ATOSS solutions.

Competitive Quality

- ATOSS has a leading software product (the most modern Java technology)
- ATOSS specialises in regions and industry sectors (country-specific work conditions in the Germany, Austria, Swiss region and mapping out work processes in core industries)
- ATOSS works independently of producers (no ties to hardware or large software producers) and the ATOSS solutions have a high level of compatibility (e.g. seamless integration in the ERP systems possible)
- Financial stability and balance sheet quality is excellent, which can be regarded as a competitive advantage in the software industry.
- ATOSS is a relatively large supplier (in comparison to the competition) among many much smaller suppliers, which still pose stiff competition for ATOSS.





DCF model														
	Detaile	d forecas	t period				1	ransition	nal period					Term. Value
Figures in EUR m	2016e	2017e	2018e	2019e	2020e	2021e	2022e	2023e	2024e	2025e	2026e	2027e	2028e	
Sales	50.3	56.4	63.1	69.5	76.4	84.0	90.8	98.0	105.9	112.2	116.7	121.4	126.2	
Sales change	12.0 %	12.0 %	12.0 %	10.0 %	10.0 %	10.0 %	8.0 %	8.0 %	8.0 %	6.0 %	4.0 %	4.0 %	4.0 %	2.5 %
EBIT	12.8	14.4	16.1	18.1	20.6	23.1	25.0	27.4	29.6	31.4	32.7	34.0	35.3	
EBIT-margin	25.5 %	25.5 %	25.5 %	26.0 %	27.0 %	27.5 %	27.5 %	28.0 %	28.0 %	28.0 %	28.0 %	28.0 %	28.0 %	
Tax rate (EBT)	33.0 %	33.0 %	33.0 %	35.0 %	35.0 %	35.0 %	35.0 %	35.0 %	35.0 %	35.0 %	35.0 %	35.0 %	35.0 %	
NOPAT	8.6	9.6	10.8	11.7	13.4	15.0	16.2	17.8	19.3	20.4	21.2	22.1	23.0	
Depreciation	0.7	0.8	0.9	1.4	1.3	1.3	1.4	1.5	1.6	1.7	1.8	1.8	1.9	
in % of Sales	1.5 %	1.5 %	1.5 %	2.0 %	1.7 %	1.5 %	1.5 %	1.5 %	1.5 %	1.5 %	1.5 %	1.5 %	1.5 %	
Changes in provisions	0.0	0.0	0.0	0.2	0.2	0.3	0.2	0.2	0.2	0.1	0.1	0.1	0.1	
Change in Liquidity from														
- Working Capital	0.6	0.6	0.7	0.8	0.7	0.8	0.7	0.7	0.8	0.6	0.4	0.5	0.5	
- Capex	0.7	0.7	0.7	1.0	1.1	1.3	1.4	1.5	1.6	1.7	1.8	1.8	1.9	
Capex in % of Sales	1.4 %	1.2 %	1.1 %	1.5 %	1.5 %	1.5 %	1.5 %	1.5 %	1.5 %	1.5 %	1.5 %	1.5 %	1.5 %	
Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Free Cash Flow (WACC Model)	8.0	9.2	10.3	11.5	13.1	14.6	15.8	17.3	18.7	19.9	20.9	21.7	22.6	21
PV of FCF	7.5	7.9	8.2	8.3	8.7	8.9	8.8	8.9	8.8	8.5	8.2	7.8	7.5	104
share of PVs		11.12 %						39.7	3 %					49.15 %

Model parameter				Valuation (m)			
Derivation of WACC:		Derivation of Beta:		Present values 2028e	108		
				Terminal Value	104		
Debt ratio	0.00 %	Financial Strength	1.00	Financial liabilities	0		
Cost of debt (after tax)	3.9 %	Liquidity (share)	1.50	Pension liabilities	4		
Market return	8.00 %	Cyclicality	1.50	Hybrid capital	0		
Risk free rate	2.50 %	Transparency	1.00	Minority interest	0		
		Others	1.00	Market val. of investments	0		
				Liquidity	20	No. of shares (m)	4.0
WACC	9.10 %	Beta	1.20	Equity Value	228	Value per share (EUR)	57.38

Sensitivity	/ Value	per Share	(EUR)

		Terminal (Growth								Delta EBIT	-margin					
Beta	WACC	1.75 %	2.00 %	2.25 %	2.50 %	2.75 %	3.00 %	3.25 %	Beta	WACC	-1.5 pp	-1.0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
1.38	10.1 %	48.01	48.58	49.18	49.83	50.52	51.26	52.05	1.38	10.1 %	47.14	48.04	48.93	49.83	50.73	51.62	52.52
1.29	9.6 %	51.14	51.82	52.55	53.33	54.18	55.08	56.05	1.29	9.6 %	50.44	51.40	52.37	53.33	54.30	55.27	56.23
1.25	9.4 %	52.86	53.61	54.42	55.28	56.21	57.22	58.30	1.25	9.4 %	52.27	53.27	54.28	55.28	56.29	57.29	58.30
1.20	9.1 %	54.70	55.53	56.42	57.38	58.41	59.53	60.74	1.20	9.1 %	54.24	55.29	56.33	57.38	58.42	59.47	60.52
1.15	8.9 %	56.67	57.59	58.58	59.64	60.79	62.04	63.40	1.15	8.9 %	56.37	57.46	58.55	59.64	60.73	61.82	62.91
1.11	8.6 %	58.79	59.81	60.91	62.09	63.38	64.78	66.31	1.11	8.6 %	58.67	59.81	60.95	62.09	63.23	64.37	65.51
1.02	8.1 %	63.55	64.80	66.17	67.65	69.28	71.06	73.03	1.02	8.1 %	63.90	65.15	66.40	67.65	68.90	70.16	71.41

- In the DCF model, a moderate continuation of the constant growth of the past years is anticipated.
- A margin improvement due to economies of scale is not assumed.
- The long-term margin remains at a high level




Valuation							
	2012	2013	2014	2015	2016e	2017e	2018e
Price / Book	3.4 x	9.1 x	7.9 x	9.7 x	17.0 x	12.7 x	10.1 x
Book value per share ex intangibles	5.92	2.93	3.72	4.72	4.06	5.48	7.02
EV / Sales	1.7 x	2.7 x	2.6 x	3.7 x	5.2 x	4.5 x	4.0 x
EV / EBITDA	7.0 x	10.5 x	9.9 x	13.7 x	19.1 x	16.8 x	14.9 x
EV / EBIT	7.5 x	11.3 x	10.4 x	14.5 x	20.2 x	17.7 x	15.8 x
EV / EBIT adj.*	7.5 x	11.3 x	10.4 x	14.5 x	20.2 x	17.7 x	15.8 x
P/FCF	26.9 x	26.2 x	15.3 x	25.2 x	34.4 x	30.1 x	27.2 x
P/E	14.0 x	37.3 x	16.8 x	24.3 x	32.2 x	28.7 x	26.1 x
P / E adj.*	14.0 x	37.3 x	16.8 x	24.3 x	32.2 x	28.7 x	26.1 x
Dividend Yield	17.9 %	2.7 %	3.0 %	6.0 %	1.6 %	1.7 %	1.9 %
Free Cash Flow Yield Potential	8.7 %	7.7 %	6.5 %	4.8 %	3.4 %	3.9 %	4.4 %
*Adjustments made for: -							



In EUR m	2012	2013	2014	2015	2016e	2017e	2018e
Sales	33.0	35.5	39.7	44.9	50.3	56.4	63.1
Change Sales yoy	4.5 %	7.6 %	11.8 %	13.2 %	12.0 %	12.0 %	12.0 %
COGS	9.7	10.3	12.4	14.1	14.6	16.3	18.3
Gross profit	23.4	25.2	27.3	30.8	35.7	40.0	44.8
Gross margin	70.8 %	71.0 %	68.8 %	68.5 %	71.0 %	71.0 %	71.0 %
Research and development	7.1	7.5	8.0	8.7	11.1	12.4	13.9
Sales and marketing	5.7	6.2	6.4	7.4	8.6	9.6	10.7
Administration expenses	2.9	3.1	3.3	3.5	3.8	4.2	4.7
Other operating expenses	0.1	0.1	0.0	0.2	0.0	0.0	0.0
Other operating income	0.0	0.1	0.3	0.3	0.5	0.6	0.6
Unfrequent items	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	8.2	9.0	10.3	12.0	13.6	15.2	17.0
Margin	24.8 %	25.4 %	26.0 %	26.8 %	27.0 %	27.0 %	27.0 %
Depreciation of fixed assets	0.6	0.4	0.4	0.6	0.6	0.7	0.8
EBITA	7.6	8.6	9.9	11.5	12.9	14.5	16.2
Amortisation of intangible fixed assets	0.0	0.1	0.1	0.1	0.1	0.1	0.1
Goodwill amortization	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	7.6	8.4	9.8	11.3	12.8	14.4	16.1
Margin	23.1 %	23.7 %	24.7 %	25.2 %	25.5 %	25.5 %	25.5 %
EBIT adj.	7.6	8.4	9.8	11.3	12.8	14.4	16.1
Interest income	1.2	0.4	0.6	0.1	0.1	0.1	0.1
Interest expenses	0.3	4.6	0.1	0.1	0.1	0.1	0.1
Other financial income (loss)	0.0	0.2	0.0	0.0	0.0	0.0	0.0
EBT	8.5	4.2	10.3	11.3	12.8	14.4	16.1
Margin	25.8 %	11.7 %	25.9 %	25.2 %	25.5 %	25.5 %	25.5 %
Total taxes	2.8	1.3	3.3	3.7	4.2	4.7	5.3
Net income from continuing operations	5.8	2.9	7.0	7.6	8.6	9.6	10.8
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income before minorities	5.8	2.9	7.0	7.6	8.6	9.6	10.8
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	5.8	2.9	7.0	7.6	8.6	9.6	10.8
Margin	17.5 %	8.0 %	17.7 %	16.9 %	17.1 %	17.1 %	17.1 %
Number of shares, average	4.0	4.0	4.0	4.0	4.0	4.0	4.0
EPS	1.45	0.72	1.77	1.91	2.16	2.42	2.71
EPS adj.	1.45	0.72	1.77	1.91	2.16	2.42	2.71
*Adjustments made for:							

Guidance: Continued positive developement of the company, EBIT margin 25 %

Financial Ratios							
	2012	2013	2014	2015	2016e	2017e	2018e
Total Operating Costs / Sales	47.7 %	47.3 %	44.2 %	43.3 %	45.5 %	45.5 %	45.5 %
Operating Leverage	0.9 x	1.4 x	1.4 x	1.2 x	1.1 x	1.0 x	1.0 x
EBITDA / Interest expenses	27.9 x	2.0 x	105.8 x	100.6 x	135.7 x	152.0 x	170.3 x
Tax rate (EBT)	32.5 %	31.3 %	31.7 %	33.0 %	33.0 %	33.0 %	33.0 %
Dividend Payout Ratio	249.9 %	100.4 %	49.8 %	146.7 %	49.9 %	50.0 %	50.1 %
Sales per Employee	121,364	127,258	135,460	146,103	155,843	166,233	177,315




Source: Warburg Research Source: Warburg Research Source: Warburg Research



Consolidated balance sheet							
In EUR m	2012	2013	2014	2015	2016e	2017e	20186
Assets							
Goodwill and other intangible assets	0.1	0.1	0.1	0.2	0.1	-0.1	-0.2
thereof other intangible assets	0.1	0.1	0.1	0.2	0.1	-0.1	-0.2
thereof Goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Property, plant and equipment	2.8	2.7	2.7	2.7	2.7	2.7	2.6
Financial assets	0.6	0.4	0.5	0.4	0.4	0.4	0.4
Other long-term assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Fixed assets	3.5	3.3	3.3	3.3	3.2	3.1	2.8
Inventories	0.0	0.0	0.0	0.0	0.0	0.0	0.1
Accounts receivable	3.2	3.0	3.8	4.5	6.1	6.8	7.6
Liquid assets	24.9	14.5	20.1	23.9	20.8	25.7	31.2
Other short-term assets	1.6	1.8	1.5	1.6	1.6	1.8	2.0
Current assets	29.7	19.4	25.5	30.0	28.5	34.3	40.9
Total Assets	33.2	22.7	28.9	33.3	31.7	37.4	43.7
Liabilities and shareholders' equity							
Subscribed capital	4.0	4.0	4.0	4.0	4.0	4.0	4.0
Capital reserve	-0.7	-0.7	-0.7	-0.7	-0.7	-0.7	-0.7
Retained earnings	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other equity components	20.3	8.4	11.6	15.6	12.9	18.4	24.4
Shareholders' equity	23.7	11.8	14.9	18.9	16.2	21.7	27.7
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total equity	23.7	11.8	14.9	18.9	16.2	21.7	27.7
Provisions	2.2	2.9	5.6	5.1	5.2	5.3	5.4
thereof provisions for pensions and similar obligations	1.7	2.7	4.2	4.3	4.3	4.3	4.3
Financial liabilities (total)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
thereof short-term financial liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accounts payable	0.4	0.3	0.3	0.3	1.3	1.4	1.6
Other liabilities	7.0	7.7	8.0	9.0	9.0	9.0	9.0
Liabilities	9.5	10.9	13.9	14.4	15.5	15.7	16.0
Total liabilities and shareholders' equity	33.2	22.7	28.9	33.3	31.7	37.4	43.7

Financial Ratios							
	2012	2013	2014	2015	2016e	2017e	2018e
Efficiency of Capital Employment							
Operating Assets Turnover	5.8 x	6.5 x	6.3 x	6.6 x	6.7 x	7.0 x	7.3 x
Capital Employed Turnover	70.4 x	-486.2 x	-40.4 x	-69.1 x	-180.0 x	151.5 x	76.6 x
ROA	165.5 %	87.0 %	210.9 %	230.4 %	266.1 %	312.4 %	380.4 %
Return on Capital							
ROCE (NOPAT)	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
ROE	25.7 %	16.1 %	52.6 %	44.8 %	48.9 %	50.7 %	43.6 %
Adj. ROE	25.7 %	16.1 %	52.6 %	44.8 %	48.9 %	50.7 %	43.6 %
Balance sheet quality							
Net Debt	-23.2	-11.9	-15.9	-19.6	-16.5	-21.4	-26.9
Net Financial Debt	-24.9	-14.5	-20.1	-23.9	-20.8	-25.7	-31.2
Net Gearing	-98.0 %	-100.6 %	-106.6 %	-103.4 %	-101.7 %	-98.3 %	-97.0 %
Net Fin. Debt / EBITDA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Book Value / Share	6.0	3.0	3.8	4.8	4.1	5.5	7.0
Book value per share ex intangibles	5.9	2.9	3.7	4.7	4.1	5.5	7.0




Source: Warburg Research Source: Warburg Research Source: Warburg Research



Consolidated cash flow statement							
In EUR m	2012	2013	2014	2015	2016e	2017e	2018e
Net income	5.8	2.9	7.0	7.6	8.6	9.6	10.8
Depreciation of fixed assets	0.6	0.4	0.4	0.6	0.6	0.7	0.8
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	0.0	0.1	0.1	0.1	0.1	0.1	0.1
Increase/decrease in long-term provisions	0.0	1.0	1.5	0.1	0.0	0.0	0.0
Other non-cash income and expenses	-0.7	0.0	0.0	0.0	0.0	0.0	0.0
Cash Flow	5.6	4.4	9.1	8.4	9.3	10.5	11.7
Increase / decrease in inventory	0.0	0.0	0.0	0.0	0.0	0.0	-0.1
Increase / decrease in accounts receivable	-0.6	0.2	-0.8	-0.6	-1.6	-0.7	-0.8
Increase / decrease in accounts payable	-0.4	0.0	0.0	0.0	1.0	0.1	0.2
Increase / decrease in other working capital positions	-1.2	0.0	0.0	0.2	0.0	0.0	0.0
Increase / decrease in working capital (total)	-2.3	0.2	-0.8	-0.4	-0.6	-0.6	-0.7
Net cash provided by operating activities	3.4	4.6	8.3	8.0	8.7	9.9	11.0
Investments in intangible assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Investments in property, plant and equipment	-0.4	-0.5	-0.5	-0.7	-0.7	-0.7	-0.7
Payments for acquisitions	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Financial investments	-6.4	0.0	0.0	0.0	0.0	0.0	0.0
Income from asset disposals	0.0	0.0	0.0	-1.1	0.0	0.0	0.0
Net cash provided by investing activities	-6.8	-0.5	-0.5	-1.8	-0.7	-0.7	-0.7
Change in financial liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Dividends paid	-2.8	-14.4	-2.9	-3.5	-11.1	-4.3	-4.8
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net cash provided by financing activities	-2.8	-14.4	-2.9	-3.5	-11.1	-4.3	-4.8
Change in liquid funds	-6.3	-10.3	4.9	2.7	-3.1	4.9	5.5
Effects of exchange-rate changes on cash	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cash and cash equivalent at end of period	18.0	14.5	19.4	22.8	20.8	25.7	31.2

Financial Ratios							
	2012	2013	2014	2015	2016e	2017e	2018e
Cash Flow							
FCF	3.0	4.1	7.7	7.3	8.0	9.2	10.3
Free Cash Flow / Sales	9.1 %	11.5 %	19.5 %	16.3 %	16.0 %	16.3 %	16.4 %
Free Cash Flow Potential	5.0	7.3	6.6	7.9	8.9	10.0	11.3
Free Cash Flow / Net Profit	52.0 %	142.8 %	110.1 %	96.5 %	93.4 %	95.3 %	95.8 %
Interest Received / Avg. Cash	4.9 %	2.2 %	3.5 %	0.4 %	0.4 %	0.4 %	0.4 %
Interest Paid / Avg. Debt	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Management of Funds							
Investment ratio	1.1 %	1.5 %	1.3 %	1.5 %	1.4 %	1.2 %	1.1 %
Maint. Capex / Sales	1.3 %	1.2 %	1.1 %	1.0 %	0.9 %	0.8 %	0.7 %
Capex / Dep	63.2 %	94.3 %	101.5 %	98.7 %	91.9 %	82.1 %	73.3 %
Avg. Working Capital / Sales	7.1 %	7.9 %	7.9 %	8.6 %	8.9 %	9.0 %	9.1 %
Trade Debtors / Trade Creditors	910.1 %	926.6 %	1199.2 %	1487.0 %	469.2 %	485.7 %	475.0 %
Inventory Turnover	1206.6 x	1286.3 x	1802.9 x	1707.9 x	n.a.	n.a.	183.1 x
Receivables collection period (days)	36	31	35	36	44	44	44
Payables payment period (days)	13	12	9	8	33	31	32
Cash conversion cycle (Days)	-13	-11	-9	-8	n.a.	n.a.	-30





LEGAL DISCLAIMER

This research report was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It contains selected information and does not purport to be complete. The report is based on publicly available information and data ("the information") believed to be accurate and complete. Warburg Research GmbH neither does examine the information to be accurate and complete, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these analyses concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this research report, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this document. Provided a research report is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This research report does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this report are subject to change without notice. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §34B (1) OF THE GERMAN SECURITIES TRADING ACT (WHPG) AND THE ORDINANCE ON THE ANALYSIS OF FINANCIAL INSTRUMENTS (FINANV)

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Potential, Peer Group Comparison or Sum of the Parts Model. The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

In accordance with § 5 (4) of the Ordinance on the Analysis of Financial Instruments (FinAnV) Warburg Research GmbH has implemented additional internal and organisational arrangements to prevent or to deal with conflicts of interest. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity - directly or indirectly - from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg Group.

All prices of financial instruments given in this financial analysis are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin.

SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.



Additional information for clients in the United States

- 1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.
- 2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934.
- 3. Any recipient of the Report should effect transactions in the securities discussed in the Report only through J.P.P. Euro-Securities, Inc., Delaware.
- 4. J.P.P. Euro-Securities, Inc. does not accept or receive any compensation of any kind for the dissemination of the research reports from Warburg.

Reference in accordance with section 34b of the German Securities Trading Act (WpHG) and the Ordinance on the Analysis of Financial Instruments (FinAnV) regarding possible conflicts of interest with the analysed company:

-1-Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a **share of more than 5%** of the equity capital of the analysed company. -2-Warburg Research, or an affiliated company, within the last twelve months participated in the management of a consortium for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the financial analysis. -3-Companies affiliated with Warburg Research manage financial instruments, which are, or the issuers of which are, subject of the financial analysis, in a market based on the provision of buy or sell contracts Warburg Research, or an affiliated company, were in the last twelve months bound by a service agreement with the issuers, who are themselves or their financial instruments are, subject of the financial analysis, in connection with investment banking business for which a service or a promise of a service emanated. The company compiling the analysis or an affiliated company had reached an agreement on the compilation of the financial analysis with the analysed company. Companies affiliated with Warburg Research regularly trade financial instruments of the analysed company or derivatives of these. -7.

This report has been made accessible to the company analysed.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
ATOSS	5	http://www.mmwarburg.com/disclaimer/disclaimer_en/DE0005104400.htm

relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

The company preparing the analysis as well as its affiliated companies and employees have other important interests in



INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.
<u>"_"</u>	Rating suspended:	The available information currently does not permit an evaluation of the company.

WARBURG RESEARCH GMBH - RESEARCH UNIVERSE BY RATING						
Rating	Number of stocks	% of Universe				
Buy	119	63				
Hold	63	33				
Sell	5	3				
Rating suspended	3	2				
Total	190	100				

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment banking services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	23	72
Hold	8	25
Sell	0	0
Rating suspended	1	3
Total	32	100

PRICE AND RATING HISTORY ATOSS AS OF 26.04.2016



The chart has markings if Warburg Research GmbH changed its rating in the last 12 months. Every marking represents the date and closing price on the day of the rating change.



EQUITIES.			
EQUITIES			
Roland Rapelius Head of Equities	+49 40 3282-2673 rrapelius@mmwarburg.com		
RESEARCH			
Michael Heider	+49 40 309537-280	Andreas Pläsier	+49 40 309537-246
Head of Research	mheider@warburg-research.com	Banks, Financial Services	aplaesier@warburg-research.com
Henner Rüschmeier Head of Research	+49 40 309537-270 hrueschmeier@warburg-research.com	Jochen Reichert Telco, Internet, Media	+49 40 309537-130 jreichert@warburg-research.com
Lucas Boventer	+49 40 309537-290	J. Moritz Rieser	+49 40 309537-260
Renewables, Internet, Media	lboventer@warburg-research.com	Real Estate	mrieser@warburg-research.com
Christian Cohrs	+49 40 309537-175	Arash Roshan Zamir	+49 40 309537-155
Engineering, Logistics Felix Ellmann	ccohrs@warburg-research.com	Cap. Goods, Renewables Malte Schaumann	aroshanzamir@warburg-research.com
Software, IT	+49 40 309537-120 fellmann@warburg-research.com	Technology	+49 40 309537-170 mschaumann@warburg-research.com
Jörg Philipp Frey	+49 40 309537-258	Oliver Schwarz	+49 40 309537-250
Retail, Consumer Goods	jfrey@warburg-research.com	Chemicals, Agriculture	oschwarz@warburg-research.com
Harald Hof Medtech	+49 40 309537-125	Marc-René Tonn Automobiles, Car Suppliers	+49 40 309537-259
Ulrich Huwald	hhof@warburg-research.com +49 40 309537-255	Björn Voss	mtonn@warburg-research.com +49 40 309537-254
Health Care, Pharma	uhuwald@warburg-research.com	Steel, Car Suppliers	bvoss@warburg-research.com
Thilo Kleibauer	+49 40 309537-257	Alexander Wahl	+49 40 309537-230
Retail, Consumer Goods	tkleibauer@warburg-research.com	Other	awahl@warburg-research.com
Eggert Kuls Engineering	+49 40 309537-256 ekuls@warburg-research.com	Andreas Wolf Software, IT	+49 40 309537-140 awolf@warburg-research.com
INSTITUTIONAL EQU		Contract, II	amonig marbang recoderon.com
Holger Nass	+49 40 3282-2669	Marie-Therese Grübner	+49 40 3282-2630
Head of Equity Sales, USA	hnass@mmwarburg.com	France, Switzerland	mgruebner@mmwarburg.com
Klaus Schilling	+49 40 3282-2664	Michael Kriszun	+49 40 3282-2695
Dep. Head of Equity Sales, GER	kschilling@mmwarburg.com	United Kingdom	mkriszun@mmwarburg.com
Tim Beckmann United Kingdom	+49 40 3282-2665 tbeckmann@mmwarburg.com	Marc Niemann Germany	+49 40 3282-2660 mniemann@mmwarburg.com
Lyubka Bogdanova	+49 69 5050-7411	Fabian Roggemann	+49 40 3282-2667
United Kingdom, Australia	lbogdanova@mmwarburg.com	USA	froggemann@mmwarburg.com
Jens Buchmüller	+49 69 5050-7415	Sanjay Oberoi	+49 69 5050-7410
Scandinavia, Austria Paul Dontenwill	jbuchmueller@mmwarburg.com +49 40 3282-2666	United Kingdom Juliane Willenbruch	soberoi@mmwarburg.com +49 40 3282-2694
USA	pdontenwill@mmwarburg.com	Roadshow/Marketing	jwillenbruch@mmwarburg.com
Matthias Fritsch	+49 40 3282-2696	•	
United Kingdom	mfritsch@mmwarburg.com		
SALES TRADING			
Oliver Merckel	+49 40 3282-2634	Jörg Treptow	+49 40 3262-2658
Head of Sales Trading Michael Ilgenstein	omerckel@mmwarburg.com +49 40 3282-2700	Sales Trading Jan Walter	jtreptow@mmwarburg.com +49 40 3262-2662
Sales Trading	milgenstein@mmwarburg.com	Sales Trading	jwalter@mmwarburg.com
Bastian Quast	+49 40 3282-2701	•	, ,
Sales Trading	bquast@mmwarburg.com		
MACRO RESEARCH			
Carsten Klude Macro Research	+49 40 3282-2572 cklude@mmwarburg.com	Dr. Christian Jasperneite Investment Strategy	+49 40 3282-2439 cjasperneite@mmwarburg.com
Our research can be	found under:		
Warburg Research	research.mmwarburg.com/en/index.html	Thomson	www.thomson.com
Bloomberg	MMWA GO	Reuters	www.knowledge.reuters.com
FactSet	www.factset.com	Capital IQ	www.capitaliq.com
For access please cont	act:		
Andrea Schaper	+49 40 3282-2632	Kerstin Muthig	+49 40 3282-2703
Sales Assistance	aschaper@mmwarburg.com	Sales Assistance	kmuthig@mmwarburg.com